Research programme: apoptosis stimulants - TetraLogic Pharmaceuticals

Drug Profile

Research programme: apoptosis stimulants - TetraLogic Pharmaceuticals

Alternative Names: GT 12726; GT 12794; GT 12810; GT 12869; GT 12882; GT 12911

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Princeton University
  • Developer TetraLogic Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Jan 2014 Preclinical development is ongoing in USA
  • 19 Nov 2009 Preclinical pharmacodynamics, pharmacokinetics and safety data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 20 Aug 2009 Pharmacodynamics data presented at the 238th American Chemical Society National Meeting (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top